Show simple item record

dc.contributor.authorGuo, T
dc.contributor.authorWang, Y
dc.contributor.authorJia, J
dc.contributor.authorMao, X
dc.contributor.authorStankiewicz, E
dc.contributor.authorScandura, G
dc.contributor.authorBurke, E
dc.contributor.authorXu, L
dc.contributor.authorMarzec, J
dc.contributor.authorDavies, CR
dc.contributor.authorLu, JJ
dc.contributor.authorRajan, P
dc.contributor.authorGrey, A
dc.contributor.authorTipples, K
dc.contributor.authorHines, J
dc.contributor.authorKudahetti, S
dc.contributor.authorOliver, T
dc.contributor.authorPowles, T
dc.contributor.authorAlifrangis, C
dc.contributor.authorKohli, M
dc.contributor.authorShaw, G
dc.contributor.authorWang, W
dc.contributor.authorFeng, N
dc.contributor.authorShamash, J
dc.contributor.authorBerney, D
dc.contributor.authorWang, L
dc.contributor.authorLu, Y-J
dc.date.accessioned2021-02-25T10:12:42Z
dc.date.available2020-11-30
dc.date.available2021-02-25T10:12:42Z
dc.date.issued2021-01-07
dc.identifier.issn2296-634X
dc.identifier.otherARTN 602493
dc.identifier.urihttps://qmro.qmul.ac.uk/xmlui/handle/123456789/70501
dc.description.abstractCastration-resistant prostate cancer (CRPC) is the major cause of death from prostate cancer. Biomarkers to improve early detection and prediction of CRPC especially using non-invasive liquid biopsies could improve outcomes. Therefore, we investigated the plasma exosomal miRNAs associated with CRPC and their potential for development into non-invasive early detection biomarkers for resistance to treatment. RNA-sequencing, which generated approximately five million reads per patient, was performed to identify differentially expressed plasma exosomal miRNAs in 24 treatment-naive prostate cancer and 24 CRPC patients. RT-qPCR was used to confirm the differential expressions of six exosomal miRNAs, miR-423-3p, miR-320a, miR-99a-5p, miR-320d, miR-320b, and miR-150-5p (p = 7.3 × 10−8, 0.0020, 0.018, 0.0028, 0.0013, and 0.0058, respectively) firstly in a validation cohort of 108 treatment-naive prostate cancer and 42 CRPC patients. The most significant differentially expressed miRNA, miR-423-3p, was shown to be associated with CRPC with area under the ROC curve (AUC) = 0.784. Combining miR-423-3p with prostate-specific antigen (PSA) enhanced the prediction of CRPC (AUC = 0.908). A separate research center validation with 30 treatment-naive and 30 CRPC patients also confirmed the differential expression of miR-423-3p (p = 0.016). Finally, plasma exosomal miR-423-3p expression in CRPC patients was compared to 36 non-CRPC patients under androgen depletion therapy, which showed significantly higher expression in CRPC than treated non-CRPC patients (p < 0.0001) with AUC = 0.879 to predict CRPC with no difference between treatment-naive and treated non-CRPC patients. Therefore, our findings demonstrate that a number of plasma exosomal miRNAs are associated with CRPC and miR-423-3p may serve as a biomarker for early detection/prediction of castration-resistance.en_US
dc.publisherFrontiersen_US
dc.relation.ispartofFRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
dc.rightsThis is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subjectprostate canceren_US
dc.subjectcastration-resistance developmenten_US
dc.subjectbiomarkeren_US
dc.subjectplasma exosome miRNAen_US
dc.subjectmiR-423-3pen_US
dc.titleThe Identification of Plasma Exosomal miR-423-3p as a Potential Predictive Biomarker for Prostate Cancer Castration-Resistance Development by Plasma Exosomal miRNA Sequencingen_US
dc.typeArticleen_US
dc.rights.holder© 2021 Guo, Wang, Jia, Mao, Stankiewicz, Scandura, Burke, Xu, Marzec, Davies, Lu, Rajan, Grey, Tipples, Hines, Kudahetti, Oliver, Powles, Alifrangis, Kohli, Shaw, Wang, Feng, Shamash, Berney, Wang and Lu.
dc.identifier.doi10.3389/fcell.2020.602493
pubs.author-urlhttp://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000609131900001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6aen_US
pubs.notesNot knownen_US
pubs.publication-statusPublisheden_US
pubs.volume8en_US
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US
qmul.funderSam68 and hnRNPA2 in prostate cancer::Cancer Research UKen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Except where otherwise noted, this item's license is described as This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.